Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Progenics Pharmaceuticals, Inc. (PGNX), Halozyme Therapeutics, Inc. (HALO), Astex Pharmaceuticals, Inc. (ASTX): Three Humongous Health-Care Stocks This Week

Page 1 of 2

With August winding down, summer won’t be around much longer. Several health-care stocks still had hot days this past week, though. Here are three of the hottest in the market.

 Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Pharmaceutical phoenix
Like the mythicial phoenix, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) could be rising from the ashes. Shares soared by 16% this week.

It was only a little over a year ago when Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and partner Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) received the news that the Food and Drug Administration wouldn’t approve Relistor as a treatment of opioid-induced constipation in adult patients with chronic pain not caused by cancer. That rejection caused Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares to immediately lose around half their value. The stock continued to fall over the next few months.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced in June that an FDA advisory committee would again review Relistor’s supplement New Drug Application, or sNDA, after Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) appealed the initial complete response letter received in 2012. Since June, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares have had an up-and-down ride. There wasn’t any big news over the last week to propel the stock, but it’s clearly on one of the up stretches of that ride.

Trial balloon
Shares of Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) went up like a hot-air balloon this week on positive clinical trial results. The stock climbed 11%. Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced top-line results on Wednesday from an ongoing phase 2 study of experimental drug SGI-110 in treating acute myeloid leukemia, or AML. These results indicated an overall complete remission rate of 25%. The market clearly liked what it heard, with Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) shares jumping as much as 26% in intraday trading before settling down a bit.

This has proved to be a good year for Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) so far. The stock is up a whopping 136% year to date. Continued sales strength for myelodysplastic syndromes drug Dacogen combined with solid progression in the pipeline have made Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) one of 2013’s big winners.

Inside straight
Shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have seen their account balances go up in nearly a straight line since mid-August. This past week was no exception, with Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares climbing 11%.

These nice gains have been propelled in large part by insider purchases. Kathryn Falberg, a director with Halozyme Therapeutics, Inc. (NASDAQ:HALO), bought 100,000 shares in August. It’s usually encouraging to outside investors to see insiders scooping up a large number of shares on the open market.

Page 1 of 2
Loading Comments...